GlassScriptPhysician profile
Terry Michael Graber
NPI 1063465995
$5,632.47
in general payments reported to CMS, 2019-2025
27 companies · $84.96 in 2025
The $84.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $417 · 2021: $1,560 · 2022: $1,195 · 2023: $654 · 2024: $34.23 · 2025: $84.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $729.82 | 2019-2023 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $613.96 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $452.89 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $446.97 | 2019-2022 | |
| Lilly USA, LLC | $369.82 | 2019-2023 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.57 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $301.41 | 2019-2023 | Eliquis |
| Pfizer INC. | $298.82 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $288.90 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $247.85 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Sanofi-Aventis U.S. LLC | $221.03 | 2019-2022 | |
| Medtronic, INC. | $210.59 | 2022-2025 | Corevalve Evolut R |
| Avanir Pharmaceuticals, INC. | $174.23 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.38 | 2019-2021 | |
| Glaxosmithkline, LLC. | $131.35 | 2019-2023 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $85.39 | 2021-2022 | |
| Organogenesis INC. | $75.92 | 2021 | |
| Abbvie INC. | $74.66 | 2022-2023 | |
| Grifols USA, LLC | $72.79 | 2019-2023 | Prolastin-C Liquid |
| Exact Sciences Corporation | $71.42 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.17 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.00 | 2022 | |
| Allergan, INC. | $55.96 | 2019 | |
| Astellas Pharma US INC | $23.14 | 2019-2020 | |
| Lundbeck LLC | $18.08 | 2022 | |
| Eisai INC. | $14.98 | 2021 | |
| Daiichi Sankyo INC. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Graber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.